The herein described technology aims at the development of a platform of injectable hydrogels for application as drug carriers for localized delivery or in the regenerative medicine field. The use of ad-hoc synthesized poly(ether urethane)s (PEUs) as hydrogel forming materials is a common property which characterizes all the systems belonging to this platform.
Technologies
In this section it is possible to view, also through targeted research, the technologies inserted in the PROMO-TT Database. For further information on the technologies and to contact the CNR Research Teams who developed them, it is necessary to contact the Project Manager (see the references at the bottom of each record card).
Displaying results 1 - 5 of 5
Recently, nanoparticles and nanovesicles have been investigated as potential approaches for the treatment of neurodegenerative diseases. In particular, in the Biotech sector an increasingly deeper penetration of new treatment models and biological drugs based on cellular, subcellular and vesicle therapies is expected. The patent is based on the production of Myelin-based nanoVesicles (MyVes) produced by microfluidics, starting from myelin extracted from brain tissue. These vesicles find two major fields of applications as potential drugs or as supplements/nutraceuticals.
We present a new concept of ultra-compact, configurable and implantable brain computer interface (BCI). The device can be applied to monitor or stimulate, with high temporal and spatial accuracy, neural activity of the brain. It allows implementation of closed-loop algorithms in real time applications. The system can be also used in vitro to monitor or induce cell growth or as tDCS tool. The system can be customized (microelectrodes materials and shapes) to guarantee the best solution for the specific application.
We present a technology for the multiscale isolation (analytical-laboratory-production) of Extracellular Vesicles (VE), which overcomes the limitations of the currently available methods. As opposed to traditional "affinity-based" systems that exploit antibodies, our technology represents a radical paradigm shift in the development of affinity probes for vesicles, i.e.
Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.